Skip to main content

Table 2 Pre-hospital, periprocedural and discharge medications, agiographic findings, and procedural results of the study patients stratified by the primary endpoint

From: Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome

VariableNo such events
n = 588
Primary endpoint
n = 188
P value
Medications before admission
 Aspirin, n (%)432 (73.5)146 (77.7)0.251
 P2Y12 inhibitors, n (%)231 (39.3)79 (42.0)0.505
 Lipid-lowering drugs, n (%)430 (73.1)144 (76.6)0.346
 ACEI/ARBs, n (%)180 (30.6)74 (39.4)0.026
 β-blockers, n (%)227 (38.6)71 (37.8)0.837
 Insulin, n (%)209 (35.5)73 (38.8)0.415
 Oral antidiabetic agents, n (%)284 (48.3)92 (48.9)0.879
  Metformin, n (%)144 (24.5)44 (23.4)0.762
  Alpha-glucosidase inhibitors, n (%)123 (20.9)31 (16.5)0.185
  Sulfonylurea, n (%)135 (23.0)43 (22.9)0.980
  Dipeptidyl peptidase 4 inhibitors, n (%)8 (1.4)4 (2.1)0.687
 Any antidiabetic treatment, n (%)419 (71.3)143 (76.1)0.199
Periprocedural medications
 Aspirin, n (%)588 (100.0)182 (96.8)< 0.001
 P2Y12 inhibitors, n (%)588 (100.0)188 (100.0)
 Unfractionated heparin, n (%)482 (82.0)156 (83.0)0.754
 Bivalirudin, n (%)77 (13.1)23 (12.2)0.759
 GP IIb/IIIa receptor antagonist, n (%)100 (17.0)42 (22.3)0.100
Medications at discharge
 Aspirin, n (%)588 (100.0)182 (96.8)< 0.001
 P2Y12 inhibitors, n (%)588 (100.0)188 (100.0)
 Lipid-lowering drugs, n (%)588 (100.0)188 (100.0)
 ACEI/ARBs, n (%)283 (48.1)99 (52.7)0.279
 β-blockers, n (%)432 (73.5)130 (69.1)0.249
 Insulin, n (%)188 (32.0)76 (40.4)0.033
 Oral antidiabetic agents, n (%)318 (54.1)100 (53.2)0.831
 Metformin, n (%)90 (15.3)32 (17.0)0.574
 Alpha-glucosidase inhibitors, n (%)214 (36.4)64 (34.0)0.558
 Sulfonylurea, n (%)146 (24.8)42 (22.3)0.488
 Dipeptidyl peptidase 4 inhibitors, n (%)8 (1.4)4 (1.2)0.687
 Any antidiabetic treatment, n (%)408 (69.4)150 (79.8)0.006
Angiographic findings
 One-vessel disease, n (%)68 (11.6)6 (3.2)0.001
 Two-vessel disease, n (%)164 (27.9)30 (16.0)0.001
 LM/three-vessel disease, n (%)356 (60.5)152 (80.9)< 0.001
 Proximal LAD stenosis, n (%)291 (49.5)103 (54.8)0.206
 Restenotic lesions, n (%)61 (10.4)49 (26.1)< 0.001
 Chronic total occlusions, n (%)136 (23.1)40 (21.3)0.597
 Trifurcation or bifurcation lesions, n (%)450 (76.5)148 (78.7)0.534
 Heavy calcification lesions, n (%)193 (32.8)65 (34.6)0.657
 Lesions > 20 mm long, n (%)312 (53.1)134 (71.3)< 0.001
Procedural results
 Target vessel territory
 LM, n (%)30 (5.1)12 (6.4)0.499
 LAD, n (%)291 (49.5)91 (48.4)0.796
 LCX, n (%)168 (28.6)52 (27.7)0.809
 RCA, n (%)231 (39.3)75 (39.9)0.882
 DES use, n (%)492 (83.7)154 (81.9)0.574
 BRS use, n (%)27 (4.6)5 (2.7)0.246
 DCB use, n (%)32 (5.4)22 (11.7)0.003
 Complete revascularization, n (%)376 (63.9)80 (42.6)< 0.001
  1. ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, LM left-main artery, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, DES drug-eluting stent, BRS bioresorbable scaffold, DCB drug-coated balloon